Literature DB >> 17294067

Characterization of a familial case with primary erythromelalgia from Taiwan.

Ming-Jen Lee1, Hsin-Su Yu, Sung-Tsang Hsieh, Dennis A Stephenson, Chien-Jung Lu, Chih-Chao Yang.   

Abstract

Familial primary erythromelalgia is a rare autosomal dominant disease characterized by redness and painful episodes of the feet and hands, which is often triggered by heat or exercise. In this report, a Taiwanese family with the characteristic features of erythromelalgia is described. Genetic linkage studies established that the disease locus maps to human chromosome 2. Sequence analysis indicated that the disease segregates with a novel mutation in the alpha subunit of the voltage-gated sodium channel (SCN9A or Na(v)1.7). The change observed is predicted to cause the substitution of a highly conserved isoluecine 136 for a valine within the first segment of the transmembrane domain (D1S1). Using immuno-histochemistry to stain a skin biopsy specimen from the affected region, we demonstrate that there is a significant reduction in the number of small fibers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17294067     DOI: 10.1007/s00415-006-0328-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  12 in total

1.  Lidocaine and mexiletine therapy for erythromelalgia.

Authors:  S M Kuhnert; W J Phillips; M D Davis
Journal:  Arch Dermatol       Date:  1999-12

2.  Lidocaine patch for pain of erythromelalgia.

Authors:  Mark D P Davis; Paola Sandroni
Journal:  Arch Dermatol       Date:  2002-01

3.  Sporadic onset of erythermalgia: a gain-of-function mutation in Nav1.7.

Authors:  Chongyang Han; Anthony M Rush; Sulayman D Dib-Hajj; Song Li; Zhe Xu; Yun Wang; Lynda Tyrrell; Xiaoliang Wang; Yong Yang; Stephen G Waxman
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

4.  Impaired neurogenic control of skin perfusion in erythromelalgia.

Authors:  Cato Mørk; Ole Magne Kalgaard; Knut Kvernebo
Journal:  J Invest Dermatol       Date:  2002-04       Impact factor: 8.551

5.  Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons.

Authors:  S D Dib-Hajj; A M Rush; T R Cummins; F M Hisama; S Novella; L Tyrrell; L Marshall; S G Waxman
Journal:  Brain       Date:  2005-06-15       Impact factor: 13.501

6.  SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels.

Authors:  Joost P H Drenth; Rene H M te Morsche; Gerard Guillet; Alain Taieb; R Lee Kirby; Jan B M J Jansen
Journal:  J Invest Dermatol       Date:  2005-06       Impact factor: 8.551

7.  Erythromelalgia: a hereditary pain syndrome enters the molecular era.

Authors:  Stephen G Waxman; Sulayman D Dib-Hajj
Journal:  Ann Neurol       Date:  2005-06       Impact factor: 10.422

8.  The primary erythermalgia-susceptibility gene is located on chromosome 2q31-32.

Authors:  J P Drenth; W H Finley; G J Breedveld; L Testers; J J Michiels; G Guillet; A Taieb; R L Kirby; P Heutink
Journal:  Am J Hum Genet       Date:  2001-03-20       Impact factor: 11.025

9.  Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy.

Authors:  Theodore R Cummins; Sulayman D Dib-Hajj; Stephen G Waxman
Journal:  J Neurosci       Date:  2004-09-22       Impact factor: 6.167

10.  Erythromelalgia: vasculopathy, neuropathy, or both? A prospective study of vascular and neurophysiologic studies in erythromelalgia.

Authors:  Mark D P Davis; Paola Sandroni; Thom W Rooke; Phillip A Low
Journal:  Arch Dermatol       Date:  2003-10
View more
  21 in total

1.  The CRISPR/Cas9 system for gene editing and its potential application in pain research.

Authors:  Linlin Sun; Brianna Marie Lutz; Yuan-Xiang Tao
Journal:  Transl Perioper Pain Med       Date:  2016

Review 2.  Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders.

Authors:  Joost P H Drenth; Stephen G Waxman
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 3.  Sodium channelopathies and pain.

Authors:  Angelika Lampert; Andrias O O'Reilly; Peter Reeh; Andreas Leffler
Journal:  Pflugers Arch       Date:  2010-01-26       Impact factor: 3.657

4.  A novel SCN9A mutation responsible for primary erythromelalgia and is resistant to the treatment of sodium channel blockers.

Authors:  Min-Tzu Wu; Po-Yuan Huang; Chen-Tung Yen; Chih-Cheng Chen; Ming-Jen Lee
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

Review 5.  Are voltage-gated sodium channels on the dorsal root ganglion involved in the development of neuropathic pain?

Authors:  Wei Wang; Jianguo Gu; Yun-Qing Li; Yuan-Xiang Tao
Journal:  Mol Pain       Date:  2011-02-23       Impact factor: 3.395

Review 6.  Tetrodotoxin (TTX) as a therapeutic agent for pain.

Authors:  Francisco Rafael Nieto; Enrique José Cobos; Miguel Ángel Tejada; Cristina Sánchez-Fernández; Rafael González-Cano; Cruz Miguel Cendán
Journal:  Mar Drugs       Date:  2012-01-31       Impact factor: 6.085

7.  Paroxysmal extreme pain disorder M1627K mutation in human Nav1.7 renders DRG neurons hyperexcitable.

Authors:  Sulayman D Dib-Hajj; Mark Estacion; Brian W Jarecki; Lynda Tyrrell; Tanya Z Fischer; Mark Lawden; Theodore R Cummins; Stephen G Waxman
Journal:  Mol Pain       Date:  2008-09-19       Impact factor: 3.395

8.  A multi PDZ-domain protein Pdzd2 contributes to functional expression of sensory neuron-specific sodium channel Na(V)1.8.

Authors:  Dongmin Shao; Mark D Baker; Bjarke Abrahamsen; Francois Rugiero; Misbah Malik-Hall; W-Y Louisa Poon; Kathryn S E Cheah; Kwok-Ming Yao; John N Wood; Kenji Okuse
Journal:  Mol Cell Neurosci       Date:  2009-07-14       Impact factor: 4.314

Review 9.  The roles of sodium channels in nociception: Implications for mechanisms of pain.

Authors:  Theodore R Cummins; Patrick L Sheets; Stephen G Waxman
Journal:  Pain       Date:  2007-09-04       Impact factor: 7.926

10.  Mutation I136V alters electrophysiological properties of the Na(v)1.7 channel in a family with onset of erythromelalgia in the second decade.

Authors:  Xiaoyang Cheng; Sulayman D Dib-Hajj; Lynda Tyrrell; Stephen G Waxman
Journal:  Mol Pain       Date:  2008-01-02       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.